Why using Avastin for eye disease is so difficult

scientific article published on 01 May 2012

Why using Avastin for eye disease is so difficult is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1136/BMJ.E3012
P698PubMed publication ID22549057

P2093author name stringIngrid Torjesen
P407language of work or nameEnglishQ1860
P921main subjecteye diseaseQ3041498
bevacizumabQ413299
P304page(s)e3012
P577publication date2012-05-01
P1433published inThe BMJQ546003
P1476titleWhy using Avastin for eye disease is so difficult
P478volume344

Reverse relations

cites work (P2860)
Q24202071Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema
Q51034328Bevacizumab versus ranibizumab: why are we not playing the joker?
Q34544415Essential medicines for universal health coverage
Q58804239Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study
Q36461851The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package

Search more.